Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00. Following the transaction, the chief executive officer directly owned 1,599,154 shares in the company, valued at $57,201,738.58. This trade represents a 11.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.95, for a total transaction of $6,990,000.00.
• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00.

Roivant Sciences Stock Down 0.3%

ROIV stock traded down $0.12 during midday trading on Tuesday, reaching $34.52. The company’s stock had a trading volume of 6,905,942 shares, compared to its average volume of 7,667,241. The business’s 50-day simple moving average is $35.27 and its 200-day simple moving average is $31.04. Roivant Sciences Ltd. has a 52 week low of $11.94 and a 52 week high of $37.97. The stock has a market cap of $24.93 billion, a PE ratio of -65.13 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. As a group, equities analysts forecast that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ROIV shares. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $41.00 target price on shares of Roivant Sciences in a research note on Friday. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Finally, Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.14.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently bought and sold shares of ROIV. California State Teachers Retirement System grew its position in Roivant Sciences by 4,212.2% in the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company’s stock valued at $672,448,000 after purchasing an additional 18,560,434 shares in the last quarter. Morgan Stanley lifted its position in Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after buying an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after buying an additional 8,621,567 shares during the last quarter. Norges Bank acquired a new position in shares of Roivant Sciences during the 4th quarter worth about $112,750,000. Finally, Jefferies Financial Group Inc. bought a new position in shares of Roivant Sciences in the 4th quarter valued at about $76,272,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.